Testing Market size is USD 2.24 Billion in 2025 and is expected to reach USD 6.66 Billion by 2035 due to the increasing adoption of NIPTAustin, March 10, 2026 (GLOBE NEWSWIRE) -- According to SNS ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Recent studies in this field have indicated microbial cell-free DNA (mcfDNA) testing as a viable assay capable of identifying pathogens from the bloodstream. However, this technique has not been ...

Researchers have identified a promising way to predict bloodstream infections in children with high-risk leukemia days before the infection would be diagnosed using current standards of care. The test ...

New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for ...